Skip to content

HNGE

Hinge Health, Inc.

NYSE · USHealthcareMedical - Healthcare Information Services
$87.01-0.09%

Price as of Jul 20, 2026

HNGE earnings

Hinge Health, Inc. earnings

Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.

Next earnings
Aug 4, 2026in NaN days
EPS est $0.59 · Revenue est $201M
Track record
Beat EPS in 2 of 2 quarters
Avg surprise +28.5% (last 4 quarters)
Earnings history
Report dateEPS estEPS actualSurpriseRevenueRev. surprise
May 5, 2026$0.39$0.45+15.4%$182M+5.9%
Nov 4, 2025$0.24$0.34+41.7%$154M-1.6%

Earnings call summary

Q1 FY2026 · May 5, 2026

AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.

Management highlights

Dan Perez highlighted strong Q1 financial performance exceeding expectations. Launched migraine care program as expansion beyond MSK, demonstrating platform's ability to automate care across conditions. Commercially, pipeline was stronger than Q1 2025, interest from prospects was strong, and Hinge Select had positive momentum with 4,100 provider locations.

Guidance

Raised Q2 2026 revenue guidance to $194 - $196 million, operating income to $47 - $49 million. Full-year 2026 revenue guidance raised to $798 - $804 million, operating income to $205 - $215 million, driven by higher average eligible lives and yield improvements.

Segment performance

Revenue in Q1 2026 was $182 million, a 47% year-over-year growth from $124 million in Q1 2025. Last 12 months calculated billings reached $770 million, up 52% from $507 million in the prior year period. Gross margin was 85%, operating margin was 25% with operating income of $46 million, and free cash flow was $42 million, 10x higher year over year.

Risks & headwinds

Risks discussed include those detailed in SEC filings, including various uncertainties and assumptions affecting forward-looking statements, as per the transcript.

Analyst Q&A

  • Q: Saket Khalia asked about the migraine program market opportunity and outcomes.

    A: Dan Perez discussed the clinical need, distribution, and outcomes of the migraine program.

  • Q: Jay Linder Singh asked about yield long-term view and CMS access program.

    A: Dan Perez talked about yield potential and CMS program stance. Other questions and answers follow similarly.

Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-08-04.